Retagliptin

Retagliptin

Retagliptin

Chemical compound

Retagliptin is a DPP-4 inhibitor studied for the treatment of type 2 diabetes.[1][2][3]

Quick Facts Legal status, Identifiers ...

References

  1. [1]
    Meng, Xiangjun; Cai, Lanlan; Ren, Tianming; Sun, Dong; Gu, Jingkai (2018). "Simultaneous quantitative analysis of retagliptin and its main active metabolite in human multiple matrices by liquid chromatography tandem mass spectrometry". Analytical Methods. 10 (18): 2108–2114. doi:10.1039/C8AY00040A. ISSN 1759-9679.
  2. [2]
    Hu, Chao; Zheng, Jing; Miao, Jia; Liu, Fang; Hu, Ting-Ting; Gu, Jing-Kai; Shu, Shi-Qing; Wang, Ying; Zhu, Xiao-Hong; Liang, Mao-Zhi (2018). "[Pharmacokinetics of Phosphate Retagliptin Tabletin in Patients with Renal Dysfunction]". Sichuan da Xue Xue Bao. Yi Xue Ban = Journal of Sichuan University. Medical Science Edition. 49 (1): 74–80. ISSN 1672-173X. PMID 29737094.
  3. [3]
    Cahn, Avivit; Cernea, Simona; Raz, Itamar (2016). "An update on DPP-4 inhibitors in the management of type 2 diabetes". Expert Opinion on Emerging Drugs. 21 (4): 409–419. doi:10.1080/14728214.2016.1257608. PMID 27809608. S2CID 45825587.
Share this article:

This article uses material from the Wikipedia article Retagliptin, and is written by contributors. Text is available under a CC BY-SA 4.0 International License; additional terms may apply. Images, videos and audio are available under their respective licenses.